Cargando…

The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma Effects

PURPOSE: Poly(ADP-ribose) polymerase 1 (PARP1) is necessary for single-strand break (SSB) repair by sensing DNA breaks and facilitating DNA repair through poly ADP-ribosylation of several DNA-binding and repair proteins. Inhibition of PARP1 results in collapsed DNA replication fork and double-strand...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Hong-Yuan, Tang, Hai-Long, Zheng, Yan-Hua, Feng, Juan, Dong, Bao-Xia, Chen, Xie-Qun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9005285/ https://www.ncbi.nlm.nih.gov/pubmed/35422863 http://dx.doi.org/10.1155/2022/2800488

Ejemplares similares

PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
por: Jonuscheit, Stephanie, et al.
Publicado: (2021)

Chidamide epigenetically represses autophagy and exerts cooperative antimyeloma activity with bortezomib
por: Xu, Li, et al.
Publicado: (2020)

A case of niraparib PARP-Inhibitor induced Sweet Syndrome in gynecologic cancer
por: Badiner, Nora, et al.
Publicado: (2023)

Bisphosphonates as antimyeloma drugs
por: Modi, N D, et al.
Publicado: (2012)

MassChemSite for In-Depth Forced Degradation Analysis of PARP Inhibitors Olaparib, Rucaparib, and Niraparib
por: Bonciarelli, Stefano, et al.
Publicado: (2023)

Analogs of the novel phytohormone, strigolactone, trigger apoptosis and synergize with PARP inhibitors by inducing DNA damage and inhibiting DNA repair
por: Croglio, Michael P., et al.
Publicado: (2016)

Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas
por: Li, Hongyi, et al.
Publicado: (2020)

Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer
por: O’Brien, Shane, et al.
Publicado: (2023)

Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status
por: Genther Williams, Sybil M, et al.
Publicado: (2015)

A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models
por: Sun, Kaiming, et al.
Publicado: (2018)

Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma
por: Gill, Sonja J., et al.
Publicado: (2015)

Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts
por: Póti, Ádám, et al.
Publicado: (2018)

ATR Inhibitor Synergizes PARP Inhibitor Cytotoxicity in Homologous Recombination Repair Deficiency TK6 Cell Lines
por: Wikiniyadhanee, Rakkreat, et al.
Publicado: (2023)

Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs
por: D'Souza, Criselle, et al.
Publicado: (2021)

PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O(6)-methylguanine DNA damage in glioblastoma
por: Wu, Shaofang, et al.
Publicado: (2021)

SPDR-05 PARP INHIBITORS RESTORE TEMOZOLOMIDE SENSITIVITY IN MSH6-DEFICIENT TEMOZOLOMIDE-RESISTANT GLIOBLASTOMA CELLS
por: Higuchi, Fumi, et al.
Publicado: (2019)

PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers
por: Sisay, Mekonnen, et al.
Publicado: (2017)

Antimyeloma Effects of the Heat Shock Protein 70 Molecular Chaperone Inhibitor MAL3-101
por: Braunstein, Marc J., et al.
Publicado: (2011)

Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL
por: Suzuki, Kazuhito, et al.
Publicado: (2016)

Human mass balance study and metabolite profiling of (14)C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer
por: van Andel, Lotte, et al.
Publicado: (2017)

Niraparib for ovarian cancer
Publicado: (2021)

Homoharringtonine Exerts an Antimyeloma Effect by Promoting Excess Parkin-Dependent Mitophagy
por: Zhang, Yanyu, et al.
Publicado: (2020)

Liposome-Encapsulated Melphalan Exhibits Potent Antimyeloma Activity and Reduced Toxicity
por: Lin, Zhimei, et al.
Publicado: (2022)

PARP1-Erk synergism in proliferating cells
por: Visochek, Leonid, et al.
Publicado: (2018)

Alkannin-Induced Oxidative DNA Damage Synergizes With PARP Inhibition to Cause Cancer-Specific Cytotoxicity
por: Chang, Mingxin, et al.
Publicado: (2020)

PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling
por: van Beek, Lotte, et al.
Publicado: (2021)

Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model
por: Vo, Manh-Cuong, et al.
Publicado: (2018)

SARC025 arms 1 and 2: A phase 1 study of the poly(ADP‐ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma
por: Chugh, Rashmi, et al.
Publicado: (2020)

Pharmacological effects of Niraparib and its combination with angiogenic inhibitor in ovarian cancer
por: Liu, Huiwen, et al.
Publicado: (2023)

PARP inhibitors trap PARP2 and alter the mode of recruitment of PARP2 at DNA damage sites
por: Lin, Xiaohui, et al.
Publicado: (2022)

BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma
por: Gusyatiner, Olga, et al.
Publicado: (2021)

Glycogen synthase kinase 3β inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer
por: Zhang, Ning, et al.
Publicado: (2021)

MBRS-19. SYNERGISM OF HDAC AND PARP INHIBITORS IN MYC-DRIVEN GROUP 3 MEDULLOBLASTOMA CELLS
por: Vollmer, Johanna, et al.
Publicado: (2020)

PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth
por: Bhattacharjee, Sayani, et al.
Publicado: (2022)

Mebendazole elicits potent antimyeloma activity by inhibiting the USP5/c-Maf axis
por: Chen, Xue-han, et al.
Publicado: (2019)

Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects
por: Li, Shirong, et al.
Publicado: (2023)

Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells
por: Uddin, Md. Hafiz, et al.
Publicado: (2021)

PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer
por: Hong, Ting, et al.
Publicado: (2021)

SPDR-01 INHIBITION OF HOMOLOGOUS RECOMBINATION, PARP INHIBITOR, OR DIANHYDROGALACTITOL OVERCOMES TEMOZOLOMIDE-RESISTANCE IN GLIOMA CELLS
por: Ohba, Shigeo, et al.
Publicado: (2019)

Rucaparib and Niraparib in Advanced Ovarian Cancer
por: Redelico, Tyler
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tgc3g13t71660ancfck8v7u80j